Alnylam Pharma (ALNY) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $159.78 +1.13%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.08 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $125.9 million versus the consensus estimate of $120.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
